{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T23:45:40Z","timestamp":1775778340201,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of the study was to assess the predictors of major adverse cardiovascular events (MACE) in patients with systemic sclerosis (SSc) without pulmonary arterial hypertension. The study comprised 68 patients with SSc who were followed up for the median time of 99 (96; 107) months. The main exclusion criteria involved tricuspid regurgitation maximal velocity\u2009&gt;\u20092.8\u00a0m\/s and structural heart disease. At baseline the patients underwent clinical assessment of cardiovascular risk factors, 6-min walk test, transthoracic echocardiography and biomarker testing, including growth differentiation factor 15 (GDF-15). The primary composite endpoint was onset of MACE defined as death, myocardial infarction, myocardial revascularization and hospitalization for heart failure. The follow-up consisted of outpatient visits at 1\u00a0year intervals and telephone interview every 6\u00a0months. The baseline analysis revealed that chronic kidney disease (HR 28.13, 95%CI 4.84\u2013163.38), lung fibrosis on high resolution computed tomography (HR 4.36, 95%CI 1.04\u201318.26) and GDF-15 concentration (unit HR 1.0006, 95%CI 1.0002\u20131.0010) were independent predictors of MACE occurrence. CHLD (Chronic kidney disease, Hypertension, hyperLipidaemia, Diabetes mellitus) score was formulated which assigned 1 point for the presence of arterial hypertension, hyperlipidaemia, diabetes mellitus and chronic kidney disease. After inclusion of CHLD score in Cox proportional model, it remained the only independent predictor of MACE onset (unit HR per 1 point 3.46; 95%CI 2.06\u20135.82, p\u2009&lt;\u20090.0001). Joint assessment of traditional risk factors in the form of CHLD score may serve as a reliable predictor of long-term outcome in patients with SSc without pulmonary arterial hypertension.<\/jats:p>","DOI":"10.1038\/s41598-021-99215-x","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T11:02:54Z","timestamp":1633086174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CHLD score, a new score based on traditional risk factor evaluation and long-term cardiovascular outcomes in patients with systemic sclerosis"],"prefix":"10.1038","volume":"11","author":[{"given":"Klaudia","family":"Gieszczyk-Str\u00f3zik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej T.","family":"Wybraniec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Widuchowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ligia","family":"Brzezi\u0144ska-Wcis\u0142o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Przemys\u0142aw","family":"Kotyla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugeniusz","family":"Kucharz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Mizia-Stec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"99215_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s41927-018-0043-6","volume":"2","author":"SA Butt","year":"2018","unstructured":"Butt, S. A. et al. Trends in incidence, mortality, and causes of death associated with systemic sclerosis in Denmark between 1995 and 2015: A nationwide cohort study. BMC Rheumatol. 2, 36 (2018).","journal-title":"BMC Rheumatol."},{"key":"99215_CR2","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton, C. P. & Khanna, D. Systemic sclerosis. Lancet 390, 1685\u20131699 (2017).","journal-title":"Lancet"},{"key":"99215_CR3","first-page":"151","volume-title":"EULAR Textbook of Systemic Sclerosis","author":"Y Allanore","year":"2013","unstructured":"Allanore, Y. & Maune, C. Heart involvement. Clinical consequences of functional and pathological changes. In EULAR Textbook of Systemic Sclerosis (eds Hachulla, E. & Czirjak, L.) 151\u2013157 (BMJ publishing Group, 2013)."},{"key":"99215_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00296-016-3475-6","volume":"36","author":"H Poormoghim","year":"2016","unstructured":"Poormoghim, H. et al. Survival and causes of death in systemic sclerosis patients: A single center registry report from Iran. Rheumatol. Int. 36, 925\u2013934 (2016).","journal-title":"Rheumatol. Int."},{"key":"99215_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3390\/ph14050403","volume":"14","author":"B Ruaro","year":"2021","unstructured":"Ruaro, B. et al. The relationship between pulmonary damage and peripheral vascular manifestations in systemic sclerosis patients. Pharmaceuticals 14, 403 (2021).","journal-title":"Pharmaceuticals"},{"issue":"Suppl. 1","key":"99215_CR6","first-page":"e000782","volume":"4","author":"V Smith","year":"2018","unstructured":"Smith, V. et al. Systemic sclerosis: State of the art on clinical practice guidelines. RMD Open 4(Suppl. 1), e000782 (2018).","journal-title":"RMD Open"},{"key":"99215_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/ph14020154","volume":"14","author":"B Ruaro","year":"2021","unstructured":"Ruaro, B. et al. The treatment of lung involvement in systemic sclerosis. Pharmaceuticals 14, 154 (2021).","journal-title":"Pharmaceuticals"},{"key":"99215_CR8","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.mayocp.2019.12.015","volume":"95","author":"RD Kurmann","year":"2020","unstructured":"Kurmann, R. D. et al. Cardiovascular risk factors and atherosclerotic cardiovascular events among incident cases of systemic sclerosis: Results from a population-based cohort (1980\u20132016). Mayo Clin. Proc. 95, 1369\u20131378 (2020).","journal-title":"Mayo Clin. Proc."},{"key":"99215_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.mayocp.2020.04.044","volume":"96","author":"MO Mohamed","year":"2021","unstructured":"Mohamed, M. O. et al. Acute myocardial infarction in autoimmune rheumatologic disease: A nationwide analysis of clinical outcomes and predictors of management strategy. Mayo Clin. Proc. 96, 388\u2013399 (2021).","journal-title":"Mayo Clin. Proc."},{"key":"99215_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/acr.22152","volume":"66","author":"AJ Dave","year":"2014","unstructured":"Dave, A. J., Fiorentino, D., Lingala, B., Krishnan, E. & Chung, L. Atherosclerotic cardiovascular disease in hospitalized patients with systemic sclerosis: Higher mortality than patients with lupus and rheumatoid arthritis. Arthritis Care Res. 66, 323\u2013327 (2014).","journal-title":"Arthritis Care Res."},{"key":"99215_CR11","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1177\/2047487320916591","volume":"27","author":"G Stronati","year":"2020","unstructured":"Stronati, G. et al. Subclinical progression of systemic sclerosis-related cardiomyopathy. Eur. J. Prev. Cardiol. 27, 1876\u20131886 (2020).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"99215_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3390\/diagnostics9040220","volume":"9","author":"G Markousis-Mavrogenis","year":"2019","unstructured":"Markousis-Mavrogenis, G. et al. Cardiovascular magnetic resonance identifies high-risk systemic sclerosis patients with normal echocardiograms and provides incremental prognostic value. Diagnostics 9, 220 (2019).","journal-title":"Diagnostics"},{"key":"99215_CR13","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: An American college of rheumatology\/European league against rheumatism collaborative initiative. Ann. Rheum. Dis. 72, 1747\u20131755 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"99215_CR14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jash.2014.04.009","volume":"8","author":"MT Wybraniec","year":"2014","unstructured":"Wybraniec, M. T. et al. Low plasma renalase concentration in hypertensive patients after surgical repair of coarctation of aorta. J. Am. Soc. Hypertens. 8, 464\u2013474 (2014).","journal-title":"J. Am. Soc. Hypertens."},{"key":"99215_CR15","doi-asserted-by":"publisher","first-page":"958","DOI":"10.5603\/KP.2015.0182","volume":"73","author":"T Zdrojewski","year":"2015","unstructured":"Zdrojewski, T. et al. A new version of cardiovascular risk assessment system and risk charts calibrated for Polish population. Kardiol. Pol. 73, 958\u2013961 (2015).","journal-title":"Kardiol. Pol."},{"key":"99215_CR16","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1093\/rheumatology\/kez639","volume":"59","author":"SC Martinez","year":"2020","unstructured":"Martinez, S. C. et al. Percutaneous coronary intervention outcomes in patients with rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis. Rheumatology 59, 2512\u20132522 (2020).","journal-title":"Rheumatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99215-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99215-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99215-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:19:57Z","timestamp":1670084397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99215-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["99215"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-99215-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]},"assertion":[{"value":"30 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19598"}}